



LIVER CIRRHOSIS AND ITS COMPLICATIONS

MED341

Khalid Alswat, MD, MRCP, FACP

Associate Professor, Consultant Gastroenterologist/hepatologist

College of Medicine, King Saud University



OBJECTIVES

 To know cirrhosis, definition, causes and complications

 To understand pathophysiology of cirrhosis complications

 To known how to approach patient with cirrhosis and its complications




CIRRHOSIS: late stage of chronic liver inflammation and fibrosis, in which liver parenchyma is distorted and replaced by fibrous tissue and regenerating nodules.

NORMAL LIVER

CIRRHOTIC LIVER





- The final stage of any chronic liver inflammation
- Irreversible in its advanced stages, can be reversed in some if underlying cause is treated.



CAUSES OF CIRRHOSIS

Commonest

- Viral (HBV+- HDV, HCV)
- Non-alcoholic steatohepatitis (NASH)
- Alcoholic steatohepatitis (ASH)

AIH: Autoimmune hepatitis

PBC: Primary biliary cholangitis

PSC: Primary sclerosing cholangitis

WD: Wilson disease

A1AT: alpha-1 antitrypsin deficiency HH: hereditary hemochromatosis.

BCS: budd-chiari syndrome

HF: Heart failure

SC: sclerosing cholangitis

Other causes

Autoimmune

(AIH, PBC, PSC)

Metabolic & Hereditary

WD, AlAT, HH

Vascular

BCS, HF

Biliary

SC

- Drugs
- Others (polycystic disease, granulomatous disease....)



HISTOLOGIC STAGING Stage 0 Stage 1

Stage 2







Stage 3

Stage 4







PORTAL HYPERTENSION

-developed as complication of cirrhosis and is the beginning and requirement for most cirrhosis complications

1-Structural changes

Distortion of the liver microcirculation by: -fibrosis, nodules, angiogenesis, and vascular occlusion




2-Dynamic changes

Hepatic stellate cells are activated into myofibroblasts >> fibrogenesis and contractile potential (sinusoids, vascular smooth of the hepatic vasculature)


The dynamic changes due to:

- -increased production of vasoconstrictors (eg, endothelins, angiotensin-II, norepinephrine, thromboxane A2)
- reduced release of endothelial vasodilators (eg, nitric oxide)



Møller S et al . Scand J Gastroenterol. 2015









COMMON CIRRHOSIS COMPLICATIONS


- Variceal hemorrhage <u>(separate</u> <u>lecture)</u>
- Ascites
 - Asictes +- refractory ascites
 - Spontaneous Bacterial Peritonitis
 - Hepatorenal syndrome
- Hepatic Encephalopathy
- Pulmonary
 - Hepatic hydrothorax (similar to ascites)
 - Hepatopulmonary syndrome
 - Portopulmonary HTN
- Hepatocellular carcinoma







ASCITES







ASCITES

- Pathologic accumulation of fluid within the peritoneal cavity
- Most common complication of cirrhosis
- Causes of Ascites:
 - 1. 85% of due to cirrhosis
 - 2. 15% other causes
- 1,500 mL of fluid must be present before flank dullness is detected.
- Shifting dullness: 83% sensitivity and 56% specificity in detecting ascites.
- If no flank dullness is present less likely ascites (< 10%).




ASCITES

- First step in development of ascites
 - >>is the presence of significant portal hypertension
- Poor prognosis (unless Liver Tx)
 - Two-year survival of patients with ascites is approximately 50%



ANY NEW ASCITES SHOULD BE TAPPED AND ANALYZED!





ASCITIC FLUID ANALYSIS

	ROUTINE	OPTIONAL (WHEN THERE IS SUSPICION OF INFECTION)	UNUSUAL	UNHELPFUL
	Cell count and differential	Culture in blood culture bottles	AFB smear and culture	pH
	Albumin	Glucose	Cytology	Lactate
N.	Total protein	Lactate dehydrogenase	Triglyceride	Cholesterol
\		Amylase	Bilirubin	Fibronectin
		Gram's stain		Glycosaminoglycans

Abbreviation: AFB, acid-fast bacteria. *Adapted from Runyon.17 Reprinted with permission from Saunders Elsevier.





SERUM-TO-ASCITES ALBUMIN GRADIENT (SAAG)

High SAAG $\geq 1.1 \text{ g/dl (11 g/L)}$

- Cirrhosis
- Heart failure/constrictive pericarditis
- Alcoholic hepattis
- Budd chiari
- Massive hepatic metastases

Low SAAG <1.1 g/dL 11 g/L)

- Peritoneal carcinomatosis
- Peritoneal tuberculosis
- Secondary peritonitis
- Pancreatitis
- Serositis
- Nephrotic syndrome



INITIAL TREATMENT OF ASCITES

- 1-Dietary sodium restriction
 - Limiting sodium intake to 88 meq (2000 mg) per day
- **<u>2-Diuretics</u>** (most successful therapeutic regimen is the *combination* of <u>Spironolactone</u> and <u>Furosemide</u>)
 - Monitor electrolytes and kidney function
- Discontinue non-steroidal anti-inflammatory drugs
- Rx of underlying cause
- Evaluation for liver transplantation



REFRACTORY ASCITES

■ ~10%

Defined as ascites that:

 Unresponsive to sodium-restricted diet and high dose diuretic treatment

Or

 Development of clinically significant complications of diuretics






MANAGEMENT LINES

- Serial therapeutic paracenteses (LVP)
 +albumen (if draining> 5 L of fluid).
- Liver transplantation

 Trans-jugular intrahepatic portosystemic stent-shunt (TIPS)

Peritoneo-venous shunt





SPONTANEOUS BACTERIAL PERITONITIS (SBP)

Development of a bacterial infection in the peritoneum, despite the absence of an obvious source for the infection.

- The diagnosis is established by
 - PMN count (>250 cells/mm3)
 - A positive ascitic fluid bacterial culture
- Organisms
 - -Most cases of SBP are due to gut bacteria such as <u>E. coli</u> and <u>Klebsiella</u>
 - -sometimes others: streptococcal, staphylococcal, Enterococcus infections.

Clinical manifestations: (all, some, sometimes-none)

- Fever
- Abdominal pain/tenderness
- Altered mental status



SBP

$\mathbf{R}\mathbf{x}$

- 1. **Antibiotics:** Cefotaxime or a similar *third-generation cephalosporin* -treatment of choice for suspected SBP; it used to cover 95% of the flora including the common organisms
- 2. Albumin: to high risk patient

(the creatinine is >1 mg/dL (88 micromol/L), the blood urea nitrogen is >30 mg/dL (10.7 mmol/L), or the total bilirubin is >4 mg/dL (68 micromol/L)

- Why: help in decreasing renal failure
- Occur in 30-40% of SBP (major cause of death)



HEPATORENAL SYNDROME (HRS)

Acute renal failure (Functional)

Require presence of cirrhosis and ascites

- Dx by exclusion (NB: most common cause of acute renal failure in cirrhosis is pre-renal not HRS)
- 2 types
 - Type I: rapid, aggressive
 - Type II : slow, less aggressive
- Rx
 - Correct underlying cause
 - Albumin
 - Vasoconstrictors (Terlipression, octeriotide, midodrine, epinephrine)
 - Hemodialysis
 - Liver transplantation.



HEPATIC HYDROTHORAX

- Pleural effusion in a patient with cirrhosis and no evidence of underlying cardiopulmonary disease.
- Commonly Rt side
- 5-10% of cirrhosis patients.
- Cause: movement of ascitic fluid into the pleural space through defects in the diaphragm.
- Dx
 - reveals a transudative fluid
 - serum to fluid albumin gradient greater than 1.1
- Management similar to ascites



HEPATOPULMONARY SYNDROME (HPS)

Triad:

- Liver disease (liver disease, portal hypertension, or portosystemic shunts)
- Increased alveolar-arterial gradient while breathing room air
- Evidence for intrapulmonary vascular abnormalities, referred to as intrapulmonary vascular dilatations (shunting)

-Mild hypoxemia is common w/o HPS (ascites)



PORTOPULMONARY HTN

 Refers to the presence of pulmonary hypertension in the coexistent portal hypertension

 Prevalence in cirrhotic patients is approximately 2%

- Diagnosis:
 - Suggested by echocardiography
 - Confirmed by right heart catheterization





DEFINITION OF HE


 Hepatic encephalopathy is a brain dysfunction caused by liver insufficiency and/or portosystemic shunt.

 It manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma.



Grading system for hepatic encephalopathy

Grade	Mental status	Asterixis	EEG	
I	Euphoria/depression	Yes/no	Usually normal	
	Mild confusion			
	Slurred speech			
	Disordered sleep			
II	Lethargy Yes	Yes	Abnormal	
	Moderate confusion			
III	Marked confusion	Yes	Abnormal	
	Incoherent			
	Sleeping but arousable			
IV	Coma	No	Abnormal	







PATHOPHYSIOLOGY OF HE

Different mechanisms

- Neurotoxin (ammonia)
- Blood-to-brain transport of neurotransmitter
- activation of inhibitory neurotransmitter systems (gammaaminobutyric acid, serotonin)
- impairment of excitatory neurotransmitter systems (glutamate, catecholamines)
- >>>> enhanced neural inhibition

Sepsis, neuroinflammation, and alterations in gut flora appear to be additional factors.



PRECIPITANTS OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS

Drugs

- Benzodiazepines
- Narcotics
- Alcohol

Increased ammonia production, absorption or entry into the brain

- Excess dietary intake of protein
- Gastrointestinal bleeding
- Infection
- Electrolyte disturbances such as hypokalemia
- Constipation
- Metabolic alkalosis

Dehydration

- Vomiting
- Diarrhea
- Hemorrhage
- Diuretics
- Large volume paracentesis

Portosystemic shunting

- Radiographic or surgically placed shunts
- Spontaneous shunts

Vascular occlusion

- Hepatic vein thrombosis
- Portal vein thrombosis


• HCC



RX

- 1. Identify and treat precipitating factors for HE
- Measures to lower the blood ammonia concentration
 - Lactulose is the first choice for treatment
 - Other medications:
 - Rifaximin (nonabsorbable oral antibiotic)
 - LOLA(L-ornithine-L-aspartate, which stimulates the metabolism of ammonia)
 - Oral BCAAs (branched-chain amino acids (BCAA)





HEPATOCELLULAR CARCINOMA (HCC)

 Patients with cirrhosis have a markedly increased risk of developing hepatocellular carcinoma

- Incidence in compensated cirrhosis is ~3%/year
- 25-30% in 10 y.




TESTS TO DIAGNOSE HCC

- •Radiology (most important)
- Biopsy
- Blood tests: alphafetoprotein (AFP) high in some patients




HCC DIAGNOSIS: DYNAMIC IMAGING





During early arterial phase on CT, an HCC appears brighter than surrounding liver



In later portal venous phase, the HCC appears darker than surrounding liver (washout)

- HCCs are hypervascular
- Tumor blood supply:
 - 100% hepatic artery
- Liver parenchymal blood supply:
 - 30% hepatic artery
 - 70% portal vein
- Dynamic imaging (MRI, CT) follows tumor density with time after IV contrast bolus
 - Requires both arterial enhancement and washout



HCC RX OPTIONS

Options (depends of the stage)

- Surgical (resection, liver transplantation)
- Ablation (radiofrequency (RFA), or alcohol injection
- Embolization (TACE; trans-arterial chemoembolization or TARE: trans-arterial radio-embolization)
- Chemotherapy
- Palliative



LIVER TRANSPLANTATION

 Liver transplantation is the definitive treatment for patients with decompensated cirrhosis

 Depends upon the severity of disease, quality of life and the absence of contraindications



OTHER RECOMMENDATIONS

- Screening in cirrhosis:
 - HCC surveillance with ultrasound Q6 months
 - Endoscopy for varices

Avoidance of additional insults

- Avoidance of:
 - Alcohol
 - Herbal medications (of unknown liver safety)
 - Careful use of potentially hepatotoxic medicine if needed, and no alternatives.

Vaccinations

All cirrhotic should be vaccinated to:

- Hepatitis A and B
- Pneumococcal
- Influenza



HOW TO APPROACH PATIENT WITH CIRRHOSIS?

- Symptoms
- Signs
- Lab
- Management



CLINICAL MANIFESTATIONS

No symptoms (Most patients in early cirrhosis)

 Symptoms of cirrhosis (sometimes non-specific symptoms)

Symptoms of decompensations (when liver start to fail.)



HISTORY

Presenting symptoms	Past and drug History	Family history	Social history
1-Asymptomatic 2-Nonspecific constitutional symptoms, such as fatigue, weakness, and weight loss, etc.) 3-Symptoms of decompensation -abdominal distension due to ascites and hepatomegaly, -coffee-ground vomitus and black stool (melena) secondary to GI hemorrhage -altered mental status in hepatic encephalopathy -lower extremity swelling -jaundice, and pruritus. Other less common symptoms: respiratory (pulmonary hypertension, hepatic hydrothorax)	History of liver disease (all chronic liver disease can lead to cirrhosis) Surgery and dental Metabolic syndrome Drugs (MTX, amiodarone, amoxicillin/clavulan ateetc)	Wilson Hemochromaosis Apha-antitrypein Viral hepatitis	Risk-taking behaviors: IV drug use, sexual contact, and tattoos. Alcohol (amount type duration) Travel

CLINICAL FEATURES

Hand and nail features:	Facial features	Chest wall features	Abdominal features
Clubbing Leukonychia Palmar erythema Bruising	Muscle wasting Telangiectasia Bruising Parotid gland swelling	Gynecomastia in men Telangectasia	Collateral Bruising Hepatomegaly Splenomegaly
Cholesterol deposits Dupuytren contracture	Jaundiced sclerae Xanthelasma		Abdominal distension Hepatic bruit
Cyanosis (in patients with hepatopulmonary syndrome).			Loss of secondary Sexual hair Testicular atrophy in men.

INVESTIGATIONS IN CIRRHOSIS

Lab Test	Radiology
Moderately elevated aminotransferases (often with an AST:ALT ratio >1)	Surface nodularity
Elevated ALP (2 to 3 times the ULN)	Hypertrophy of the caudate or left lobes
Thrombocytopenia	Portosystemic collaterals*
Leukopenia/neutropenia	Ascites*
Anemia	Hepatocellular carcinoma*
Low serum albumin*	Portal/splenic/superior mesenteric vein thrombosis*
Prolonged prothrombin time/elevated INR*	
Hyperbilirubinemia*	
Hyponatremia*	
Elevated serum creatinine*	


^{*} With advanced disease

DIAGNOSIS CONFIRMATION?

To confirm and support the clinical and radio needed

1-Biopsy (histology)

- 2-Noninvasive tests
 - □Serum score systems
 - □Elastography (e.g fiobroscan)







HOW TO ASSES SEVERITY & PROGNOSIS?

□Child-Turcotte-Pugh score or Child Criteria (CPT score)...see table

□MELD score

(model for end-stage liver disease)

MELD = 3.8[serum bilirubin (mg/dL)] + 11.2[INR] + 9.6[serum creatinine (mg/dL)] + 6.4

Others



CPT SCORE FOR CLASSIFICATION OF CIRRHOSIS SEVERITY

Parameter	Points assigned			
Parameter	1	2	3	
Ascites	Absent	Slight	Moderate	
Bilirubin	<2 mg/dL (<34.2 micromol/L)	2 to 3 mg/dL (34.2 to 51.3 micromol/L)	>3 mg/dL (>51.3 micromol/L)	
Albumin	>3.5 g/dL (35 g/L)	2.8 to 3.5 g/dL (28 to 35 g/L)	<2.8 g/dL (<28 g/L)	
PT (Seconds over control) or	<4	4 to 6	>6	
INR	<1.7	1.7 to 2.3	>2.3	
Encephalopathy	None	Grade 1 to 2	Grade 3 to 4	

Score	Class	1-2 Year survival
5-6	A	100-85%
7-9	В	80-60%
10-15	C	45-35%



THANK YOU

Best of Luck

